Figure 1

IC50 values of BRAF^V600mutated melanoma cells after exposure to single agent dabrafenib or AKTi and the effects of the drugs on MAPK and the PI3K-AKT pathway. A panel of 23 BRAF^V600 mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) or AKTi (B) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM. Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib (C) or AKTi (D).